IPP and cancer: BTN3A1-stimulating antibodies or IPP transformed the immunosuppressive molecule conformation of BTN3A1 into an immunostimulatory one and elicited coordinated restoration of αβ T cell effector activity and BTN2A1-dependent γδ T lymphocyte cytotoxicity against BTN3A1+ cancer cells [46].